Abstract
Background: Endometrial cancer is the fourth most common malignancy in female population worldwide. It was estimated that 65,620 new cases and 12.590 subsequent deaths occurred in 2020 in the United States. Patients with type II and advanced endometrial cancer do not respond well to the current treatments. Therefore, endometrial cancer should be better understood in order to develop more effective treatments.
Objective: To provide an overview of genetic, metabolic characteristics, therapeutic strategies and current application of nanotechnology surrounding endometrial cancer.
Methods: Relevant articles were retrieved from Pubmed and were systematically reviewed.
Results: Hypoxia inducible factor-1 and Von Hippel-Lindau factor participated in oncogenesis and progression of endometrial cancer and Nrf2 was associated with oncogenesis. Various genetic alterations were found in endometrial cancer. Examining the abnormal X chromosome inactivation may help in the diagnosis of endometrial cancer and its precancerous lesions. Some absent tumor suppressor genes, activated oncogenes were revealed by the genetically modified mouse models. Disorders in glucose and lipid metabolism were found in endometrial cancer. Current therapeutic strategies focused on the HIF-1α pathway, the mTOR pathway as well as the immunotherapy. Nanotechnology showed great potential in endometrial cancer’s early diagnosis, metastasis determination and treatment.
Conclusion: Endometrial cancer has been understood in various aspects but the underlying mechanisms still remain relatively unknown, which might be the source of novel diagnostic, prognostic and therapeutic targets. Nanomedicine in endometrial cancer is poorly studied but the current researches showed great results in treating endometrial cancer. It needs further researching.
Keywords: Endometrial cancer, genetics, metabolic reprogramming, nanoparticles, Nrf2, HIF+1α.
Current Medicinal Chemistry
Title:Endometrial Cancer: Genetic, Metabolic Characteristics, Therapeutic Strategies and Nanomedicine
Volume: 28 Issue: 42
Author(s): Yuxuan Cai, Bei Wang, Wen Xu , Kai Liu, Yisong Gao, Chong Guo, Jinlan Chen, Mohammad Amjad Kamal and Chengfu Yuan*
Affiliation:
- College of Medical Science, China Three Gorges University, Yichang 443002, China
- Third-Grade Pharmacological Laboratory on Chinese Medicine Approved by State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang 443002, China
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang 443002, China
Keywords: Endometrial cancer, genetics, metabolic reprogramming, nanoparticles, Nrf2, HIF+1α.
Abstract:
Background: Endometrial cancer is the fourth most common malignancy in female population worldwide. It was estimated that 65,620 new cases and 12.590 subsequent deaths occurred in 2020 in the United States. Patients with type II and advanced endometrial cancer do not respond well to the current treatments. Therefore, endometrial cancer should be better understood in order to develop more effective treatments.
Objective: To provide an overview of genetic, metabolic characteristics, therapeutic strategies and current application of nanotechnology surrounding endometrial cancer.
Methods: Relevant articles were retrieved from Pubmed and were systematically reviewed.
Results: Hypoxia inducible factor-1 and Von Hippel-Lindau factor participated in oncogenesis and progression of endometrial cancer and Nrf2 was associated with oncogenesis. Various genetic alterations were found in endometrial cancer. Examining the abnormal X chromosome inactivation may help in the diagnosis of endometrial cancer and its precancerous lesions. Some absent tumor suppressor genes, activated oncogenes were revealed by the genetically modified mouse models. Disorders in glucose and lipid metabolism were found in endometrial cancer. Current therapeutic strategies focused on the HIF-1α pathway, the mTOR pathway as well as the immunotherapy. Nanotechnology showed great potential in endometrial cancer’s early diagnosis, metastasis determination and treatment.
Conclusion: Endometrial cancer has been understood in various aspects but the underlying mechanisms still remain relatively unknown, which might be the source of novel diagnostic, prognostic and therapeutic targets. Nanomedicine in endometrial cancer is poorly studied but the current researches showed great results in treating endometrial cancer. It needs further researching.
Export Options
About this article
Cite this article as:
Cai Yuxuan , Wang Bei , Xu Wen , Liu Kai , Gao Yisong , Guo Chong , Chen Jinlan , Kamal Amjad Mohammad and Yuan Chengfu *, Endometrial Cancer: Genetic, Metabolic Characteristics, Therapeutic Strategies and Nanomedicine, Current Medicinal Chemistry 2021; 28 (42) . https://dx.doi.org/10.2174/0929867328666210705144456
DOI https://dx.doi.org/10.2174/0929867328666210705144456 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Laminin and Collagen IV: Two Polypeptides as Marker of Dystocic Labor
Current Protein & Peptide Science Therapeutic Agents Based on DNA Sequence Specific Binding
Current Topics in Medicinal Chemistry Transcriptional Regulation as a Pharmacologic Intervention
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Anticancer Drugs in Liposomal Nanodevices: A Target Delivery for a Targeted Therapy
Current Topics in Medicinal Chemistry The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma
Current Cancer Drug Targets Polycystic Ovary Syndrome: A Contemporary Clinical Approach
Current Pharmaceutical Design Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy
Current Pharmaceutical Design Potential Non-coding RNAs from Microorganisms and their Therapeutic Use in the Treatment of Different Human Cancers
Current Gene Therapy Glucose Transporters in Sex Steroid Hormone Related Cancer
Current Vascular Pharmacology Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk
Current Cancer Therapy Reviews Meet Our Editorial Board Member:
Current Pharmaceutical Design Targeting Steroid Hormone Receptor Pathways in the Treatment of Hormone Dependent Cancers
Current Pharmaceutical Biotechnology An Agathokakological Tale of Δ<sup>9</sup>-THC: Exploration of Possible Biological Targets
Current Drug Targets Structural and Functional Characterization of the Proteins Responsible for N<sup>6</sup>-Methyladenosine Modification and Recognition
Current Protein & Peptide Science Targeting Therapeutic and Imaging Agents to Folate Receptor Positive Tumors
Current Pharmaceutical Biotechnology MicroRNAs: Potential Diagnostic and Therapeutic Targets for Breast Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers
Current Drug Targets Biomarkers for Systemic Therapy in Ovarian Cancer
Current Cancer Drug Targets The Effects of Soy Isoflavones in Postmenopausal Women: Clinical Review
Current Drug Therapy Novel Approaches to the Treatment of Obesity and Type 2 Diabetes Mellitus: Bioactive Leptin-Related Synthetic Peptide Analogs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery